Treatment Experiences for Patients Receiving Buprenorphine/Naloxone for Opioid Use Disorder: A Qualitative Study of Patients’ Perceptions and Attitudes

References

• Ahrnsbrak, R., Bose, J., Hedden, S. L., Lipari, R. N., & Park-Lee, E. (2017). Key substance use and mental health indicators in the United States: Results from the 2016 National Survey on Drug Use and Health. (HHS Publication No. SMA 17-5044, NSDUH Series H-52). Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration.
   Google Scholar
• American Psychiatric Association. (2021). Opioid use disorder. https://www.psychiatry.org/patients-families/addiction/opioid-use-disorder
   Google Scholar
• Barnett, P. G. (2009). Comparison of costs and utilization among buprenorphine and methadone patients. Addiction (Abingdon, England), 104(6), 982–992. https://doi.org/10.1111/j.1360-0443.2009.02539.x
   PubMed Web of Science ®Google Scholar
• Birnbaum, H. G., White, A. G., Schiller, M., Waldman, T., Cleveland, J. M., & Roland, C. L. (2011). Societal costs of prescription opioid abuse, dependence, and misuse in the United States. Pain Medicine (Malden, Mass.), 12(4), 657–667. https://doi.org/10.1111/j.1526-4637.2011.01075.x
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (2021). Suspected nonfatal drug overdoses during COVID-19. https://www.cdc.gov/drugoverdose/nonfatal/states/covid-19.html
   Google Scholar
• Chang, H.-Y., Daubresse, M., Saloner, B., & Alexander, G. C. (2019). Chronic disease medication adherence after initiation of buprenorphine for opioid use disorder. Medical Care, 57(9), 667–672. https://doi.org/10.1097/MLR.0000000000001165
   PubMed Web of Science ®Google Scholar
• Cirruzzo, C. (2021). April 28). Biden administration eases prescribing requirements for buprenorphine. US News & World Report. https://www.usnews.com/news/health-news/articles/2021-04-28/biden-administration-eases-prescribing-requirements-for-opioid-treatment-drug
   Google Scholar
• Connery, H. S., & Weiss, R. D. (2020). Discontinuing buprenorphine treatment of opioid use disorder: What do we (not) know? The American Journal of Psychiatry, 177(2), 104–106. https://doi.org/10.1176/appi.ajp.2019.19121245
   PubMed Web of Science ®Google Scholar
• Corbin, J., & Strauss, A. (2014). Basics of qualitative research: Techniques and procedures for developing grounded theory. Sage Publications.
   Google Scholar
• Degenhardt, L., Charlson, F., Mathers, B., Hall, W. D., Flaxman, A. D., Johns, N., & Vos, T. (2014). The global epidemiology and burden of opioid dependence: Results from the Global Burden of Disease 2010 Study. Addiction (Abingdon, England), 109(8), 1320–1333. https://doi.org/10.1111/add.12551
   PubMed Web of Science ®Google Scholar
• Florence, C., Luo, F., Xu, L., & Zhou, C. (2016). The economic burden of prescription opioid overdose, abuse and dependence in the United States, 2013. Medical Care, 54(10), 901–906. https://doi.org/10.1097/MLR.0000000000000625
   PubMed Web of Science ®Google Scholar
• Foley, G., & Timonen, V. (2015). Using grounded theory method to capture and analyze health care experiences. Health Services Research, 50(4), 1195–1210. https://doi.org/10.1111/1475-6773.12275
   PubMed Web of Science ®Google Scholar
• Fudala, P. J., Bridge, T. P., Herbert, S., Williford, W. O., Chiang, C. N., Jones, K., Collins, J., Raisch, D., Casadonte, P., Goldsmith, R. J., Ling, W., Malkerneker, U., McNicholas, L., Renner, J., Stine, S., & Tusel, D, Buprenorphine/Naloxone Collaborative Study Group. (2003). Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. The New England Journal of Medicine, 349(10), 949–958. https://doi.org/10.1056/NEJMoa022164
   PubMed Web of Science ®Google Scholar
• Glaser, B. G., & Strauss, A. L. (1967). The discovery of grounded theory: Strategies for research qualitative. Aldine de Gruyter.
   Google Scholar
• Gryczynski, J., Mitchell, S. G., Jaffe, J. H., O’Grady, K. E., Olsen, Y. K., & Schwartz, R. P. (2014). Leaving buprenorphine treatment: Patients’ reasons for cessation of care. Journal of Substance Abuse Treatment, 46(3), 356–361. https://doi.org/10.1016/j.jsat.2013.10.004
   PubMed Web of Science ®Google Scholar
• Hansen, R. N., Oster, G., Edelsberg, J., Woody, G. E., & Sullivan, S. D. (2011). Economic costs of nonmedical use of prescription opioids. The Clinical Journal of Pain, 27(3), 194–202. https://doi.org/10.1097/AJP.0b013e3181ff04ca
   PubMed Web of Science ®Google Scholar
• Hasan, M. M., Alam, N. M., Shi, J., Young, L. D., & Young, G. J. (2022). Long-term patient outcomes following buprenorphine/naloxone for opioud use disorder: A retropsective analysis in a commercially insured population. The American Journal of Drug and Alcohol Abuse, 48(4), 481–491. https://doi.org/10.1080/00952990.2022.2065638
   PubMed Web of Science ®Google Scholar
• Hasan, M. M., Noor-E-Alam, M., Mohite, P., Islam, M. S., Modestino, A. S., Peckham, A. M., Young, L. D., & Young, G. J. (2021). Patterns of patient discontinuation from buprenorphine/naloxone treatment for opioid use disorder: A study of a commercially insured population in Massachusetts. Journal of Substance Abuse Treatment, 131, 108416. https://doi.org/10.1016/j.jsat.2021.108416
   PubMed Web of Science ®Google Scholar
• Johnson, R. E., & McCagh, J. C. (2000). Buprenorphine and naloxone for heroin dependence. Current Psychiatry Reports, 2(6), 519–526. https://doi.org/10.1007/s11920-000-0012-8
   PubMedGoogle Scholar
• Larochelle, M. R., Bernson, D., Land, T., Stopka, T. J., Wang, N., Xuan, Z., Bagley, S. M., Liebschutz, J. M., & Walley, A. Y. (2018). Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: A cohort study. Annals of Internal Medicine, 169(3), 137–145. https://doi.org/10.7326/M17-3107
   PubMed Web of Science ®Google Scholar
• Lo-Ciganic, W.-H., Gellad, W. F., Gordon, A. J., Cochran, G., Zemaitis, M. A., Cathers, T., Kelley, D., & Donohue, J. M. (2016). Association between trajectories of buprenorphine treatment and emergency department and in‐patient utilization. Addiction (Abingdon, England), 111(5), 892–902. https://doi.org/10.1111/add.13270
   PubMed Web of Science ®Google Scholar
• Mattick, R. P., Breen, C., Kimber, J., & Davoli, M, Cochrane Drugs and Alcohol Group (2014). Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Systematic Reviews, (2), 1–67. CD002207. https://doi.org/10.1002/14651858.CD002207.pub4
   PubMed Web of Science ®Google Scholar
• McAdam-Marx, C., Roland, C. L., Cleveland, J., & Oderda, G. M. (2010). Costs of opioid abuse and misuse determined from a Medicaid database. Journal of Pain & Palliative Care Pharmacotherapy, 24(1), 5–18. https://doi.org/10.3109/15360280903544877
   PubMedGoogle Scholar
• McCance-Katz, E. F. (2004). Office-based buprenorphine treatment for opioid-dependent patients. Harvard Review of Psychiatry, 12(6), 321–338. https://doi.org/10.1080/10673220490905688
   PubMed Web of Science ®Google Scholar
• Cole, E. S., Allen, L., Austin, A., Barnes, A., Chang, C.-C H., Clark, S., Crane, D., Cunningham, P., Fry, C. E., Gordon, A. J., Hammerslag, L., Idala, D., Kennedy, S., Kim, J. Y., Krishnan, S., Lanier, P., Mahakalanda, S., Mauk, R., McDuffie, M. J., … Donohue, J. M, Medicaid Outcomes Distributed Research Network (MODRN), (2022). Outpatient follow-up and use of medications for opioid use disorder after residential treatment among Medicaid enrollees in 10 states. Drug and Alcohol Dependence, 241, 109670. https://doi.org/10.1016/j.drugalcdep.2022.109670
   PubMed Web of Science ®Google Scholar
• Morgan, J. R., Schackman, B. R., Leff, J. A., Linas, B. P., & Walley, A. Y. (2018). Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population. Journal of Substance Abuse Treatment, 85, 90–96. https://doi.org/10.1016/j.jsat.2017.07.001
   PubMed Web of Science ®Google Scholar
• Morgan, J. R., Walley, A. Y., Murphy, S. M., Chatterjee, A., Hadland, S. E., Barocas, J., Linas, B. P., & Assoumou, S. A. (2021). Characterizing initiation, use, and discontinuation of extended-release buprenorphine in a nationally representative United States commercially insured cohort. Drug and Alcohol Dependence, 225, 108764. https://doi.org/10.1016/j.drugalcdep.2021.108764
   PubMed Web of Science ®Google Scholar
• Oderda, G. M., Lake, J., Rüdell, K., Roland, C. L., & Masters, E. T. (2015). Economic burden of prescription opioid misuse and abuse: A systematic review. Journal of Pain & Palliative Care Pharmacotherapy, 29(4), 388–400. https://doi.org/10.3109/15360288.2015.1101641
   PubMedGoogle Scholar
• Parran, T., Adelman, C., Merkin, B., Pagano, M., Defranco, R., Ionescu, R., & Mace, A. (2010). Long-term outcomes of office-based buprenorphine/naloxone maintenance therapy. Drug and Alcohol Dependence, 106(1), 56–60. https://doi.org/10.1016/j.drugalcdep.2009.07.013
   PubMed Web of Science ®Google Scholar
• Shcherbakova, N., Tereso, G., Spain, J., & Roose, R. J. (2018). Treatment persistence among insured patients newly starting buprenorphine/naloxone for opioid use disorder. The Annals of Pharmacotherapy, 52(5), 405–414. https://doi.org/10.1177/1060028017751913
   PubMed Web of Science ®Google Scholar
• Sordo, L., Barrio, G., Bravo, M. J., Indave, B. I., Degenhardt, L., Wiessing, L., Ferri, M., & Pastor-Barriuso, R. (2017). Mortality risk during and after opioid substitution treatment: Systematic review and meta-analysis of cohort studies. BMJ, 357, 1–13 j1550. https://doi.org/10.1136/bmj.j1550
   PubMedGoogle Scholar
• Strassels, S. (2009). Economic burden of prescription opioid misuse and abuse. Journal of Managed Care Pharmacy : JMCP, 15(7), 556–562. https://doi.org/10.18553/jmcp.2009.15.7.556
   PubMed Web of Science ®Google Scholar
• Substance Abuse and Mental Health Services Association (2021). Medications for opioid use disorder. https://store.samhsa.gov/sites/default/files/SAMHSA_Digital_Download/PEP21-02-01-002.pdf
   Google Scholar
• Teruya, C., Schwartz, R. P., Mitchell, S. G., Hasson, A. L., Thomas, C., Buoncristiani, S. H., Hser, Y.-I., Wiest, K., Cohen, A. J., Glick, N., Jacobs, P., McLaughlin, P., & Ling, W. (2014). Patient perspectives on buprenorphine/naloxone: A qualitative study of retention during the Starting Treatment with Agonist Replacement Therapies (START) Study. Journal of Psychoactive Drugs, 46(5), 412–426. https://doi.org/10.1080/02791072.2014.921743
   PubMed Web of Science ®Google Scholar
• Tkacz, J., Severt, J., Kassed, C., & Ruetsch, C. (2012). Clinical differences between opioid abuse classes ameliorated after 1 year of buprenorphine-medication assisted treatment. Journal of Addictive Diseases, 31(2), 100–111. https://doi.org/10.1080/10550887.2012.665729
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services. (2021). Opioid crisis statistics. https://www.hhs.gov/opioids/about-the-epidemic/opioid-crisis-statistics/index.html
   Google Scholar
• Velasquez, M., Flannery, M., Badolato, R., Vittitow, A., McDonald, R. D., Tofighi, B., Garment, A. R., Giftos, J., & Lee, J. D. (2019). Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail. Addiction Science & Clinical Practice, 14(1), 37–12. https://doi.org/10.1186/s13722-019-0166-0
   PubMed Web of Science ®Google Scholar
• Volkow, N. D., Frieden, T. R., Hyde, P. S., & Cha, S. S. (2014). Medication-assisted therapies—tackling the opioid-overdose epidemic. The New England Journal of Medicine, 370(22), 2063–2066. https://doi.org/10.1056/NEJMp1402780
   PubMed Web of Science ®Google Scholar
• White, A. G., Birnbaum, H. G., Mareva, M. N., Daher, M., Vallow, S., Schein, J., & Katz, N. (2005). Direct costs of opioid abuse in an insured population in the United States. Journal of Managed Care Pharmacy, 11(6), 469–479. https://doi.org/10.18553/jmcp.2005.11.6.469
   PubMedGoogle Scholar
• Williams, A. R., Samples, H., Crystal, S., & Olfson, M. (2020). Acute care, prescription opioid use, and overdose following discontinuation of long-term buprenorphine treatment for opioid use disorder. The American Journal of Psychiatry, 177(2), 117–124. https://doi.org/10.1176/appi.ajp.2019.19060612
   PubMed Web of Science ®Google Scholar